Can I Take Glycine with BPC-157?

Why People Stack Glycine with BPC-157

Users who take BPC-157 for soft-tissue recovery, gut healing, or joint support frequently add glycine to their protocol. The logic is straightforward: glycine is the most abundant amino acid in collagen, and BPC-157's proposed tissue-repair pathways may benefit from adequate collagen substrate. A separate motivation is sleep. Glycine at 3 g before bed improved next-day alertness and reduced fatigue in a small crossover trial published in Sleep and Biological Rhythms 1. Better sleep supports recovery, which aligns with the goals of most BPC-157 users.

The Overlap in User Goals

People using BPC-157 typically want faster recovery from tendon, ligament, or gastrointestinal injury. Glycine appeals to the same population because of its documented role in wound healing and its NMDA-receptor co-agonist activity, which may support neuroplasticity during rehabilitation. The two compounds address recovery from different biochemical angles, which is part of the rationale for combining them.

What the Literature Does Not Show

No published randomized controlled trial has studied BPC-157 and glycine taken together in humans. The safety profile of this combination rests on indirect evidence: separate tolerability data for each compound plus theoretical analysis of their mechanisms. That absence of direct data is not the same as evidence of harm, but it does mean any claims about combination remain speculative.

Mechanism of Interaction: Pharmacokinetic vs. Pharmacodynamic

Understanding whether two compounds interact requires distinguishing between pharmacokinetic interactions (one changes how the other is absorbed, distributed, metabolized, or excreted) and pharmacodynamic interactions (both act on overlapping biological targets). For glycine and BPC-157, the relevant analysis falls almost entirely on the pharmacodynamic side.

Pharmacokinetic Considerations

BPC-157 is a 15-amino-acid peptide derived from gastric juice protein BPC. When taken orally, it is subject to proteolytic digestion like any peptide, though studies in rodents suggest it retains biological activity through the GI tract 2. Glycine is a free amino acid absorbed via active transport in the small intestine. These two compounds do not share metabolic enzymes (BPC-157 is not processed by cytochrome P450 isoenzymes), and glycine does not inhibit or induce any known peptide transporter. The probability of a pharmacokinetic interaction is very low.

Pharmacodynamic Overlap

Both compounds exhibit anti-inflammatory properties in animal models, but through different pathways. BPC-157 appears to modulate nitric oxide (NO) synthesis and interact with the dopamine and serotonin systems 3. Glycine acts as an inhibitory neurotransmitter in the central nervous system and activates glycine-gated chloride channels on inflammatory cells, reducing TNF-alpha and IL-6 release 4. The downstream effect of reduced inflammation is shared, but the upstream mechanisms are distinct. This means additive anti-inflammatory benefit is plausible without the risk profile of two drugs hitting the same receptor.

Collagen Synthesis: Does Glycine Actually Help BPC-157 Work Better?

Glycine makes up approximately 33% of collagen's amino acid composition. Every third residue in the collagen triple helix is glycine, a structural requirement dictated by the tight packing of the helix interior 5. Without adequate glycine, collagen production slows. A 2018 analysis in Amino Acids calculated that endogenous glycine synthesis falls roughly 10 g/day short of the amount needed for all metabolic functions, including collagen turnover 6.

The Theoretical Combination

BPC-157 has been shown to accelerate tendon-to-bone healing in rats, with histological evidence of increased collagen fiber density at the repair site 7. If BPC-157 upregulates the signaling cascade for collagen deposition, then ensuring the body has sufficient glycine substrate could remove a bottleneck. This is the theoretical basis for stacking the two. It is biologically coherent but has not been tested directly.

Practical Dosing for Collagen Support

Most glycine supplementation studies for connective tissue and metabolic health use 3 g to 15 g daily. For collagen support specifically, 5 g paired with vitamin C (taken 30 to 60 minutes before exercise) showed measurable increases in collagen synthesis markers in a small trial of engineered ligaments 8. Users combining glycine with BPC-157 for musculoskeletal recovery commonly use 3 g to 5 g daily.

Glycine, Blood Sugar, and Monitoring Considerations

Glycine has documented effects on glucose metabolism. A study in Diabetes Care (N=12 healthy subjects) found that 5 g of glycine taken with a glucose load reduced the postprandial glucose AUC by 50% compared to the glucose load alone 9. This is a meaningful effect. Separately, BPC-157 has shown gastroprotective properties in rodent ulcer models, but its effects on human glucose regulation are unstudied.

Who Needs to Monitor

For most healthy adults, glycine's glucose-lowering effect is mild and beneficial. The group that should monitor more closely includes people who:

• Take insulin or sulfonylureas for diabetes
• Use metformin alongside either compound
• Have a history of reactive hypoglycemia
• Are in a caloric deficit while using both supplements

A fasting glucose check at baseline and again two weeks after starting the combination is a reasonable precaution for anyone in these categories.

What to Watch For

Symptoms of excessive glucose lowering (lightheadedness, shakiness, cold sweats) are unlikely at standard glycine doses of 3 g to 5 g but become more relevant at 10 g+ doses or in fasted states. If these symptoms occur, reducing the glycine dose or taking it with food typically resolves the issue.

Sleep Effects and Timing

Glycine's sleep-promoting properties are well documented in small human trials. Inagawa et al. (2006) demonstrated that 3 g glycine taken before bedtime reduced sleep onset latency and improved subjective sleep quality without altering sleep architecture on polysomnography 1. The mechanism involves peripheral vasodilation and a drop in core body temperature, mediated by NMDA receptors in the suprachiasmatic nucleus 10.

Timing BPC-157 Around Glycine for Sleep

BPC-157 users who inject subcutaneously can take glycine at any time without concern for absorption interference; the routes are completely independent. For users taking oral BPC-157 capsules, spacing glycine intake by 30 to 60 minutes avoids any theoretical competition for amino acid transporters in the gut. A common protocol is oral BPC-157 on an empty stomach in the morning and glycine (3 g) 30 minutes before bed.

Does BPC-157 Affect Sleep Directly?

No human sleep data exist for BPC-157. Rodent studies suggest BPC-157 modulates serotonergic and dopaminergic pathways 3, which could theoretically influence sleep-wake regulation. Some users report vivid dreams or altered sleep quality on BPC-157, but these are anecdotal observations without controlled data.

Dose Separation and Practical Protocol

No published guideline mandates a specific dose-separation window between glycine and BPC-157. The suggestion to separate them by 30 to 60 minutes when both are taken orally is a precautionary measure based on general peptide absorption principles, not interaction-specific data.

Sample Protocol Layout

| Time | Compound | Dose | Notes | |------|----------|------|-------| | Morning, empty stomach | BPC-157 (oral) | 250 to 500 mcg | Wait 20 min before eating | | With breakfast or lunch | Glycine | 3 to 5 g | Can mix in water or food | | 30 min before bed | Glycine | 3 g | For sleep benefit |

Users who inject BPC-157 subcutaneously do not need to time it relative to glycine at all. The injection bypasses the GI tract entirely, eliminating any absorption-level concern.

Duration Considerations

Most BPC-157 protocols in the biohacking community run 4 to 8 weeks. Glycine, as an endogenous amino acid, does not require cycling and can be taken long-term. A 2020 review in Nutrients found no adverse effects from chronic glycine supplementation at doses up to 15 g/day in human studies 11.

Safety Profile of Each Compound

Glycine Safety

Glycine is classified as GRAS (Generally Recognized as Safe) by the FDA when used as a food additive. Supplemental doses of 3 g to 5 g daily are well tolerated. At 9 g+ daily, some individuals report mild GI discomfort (soft stools, nausea). Glycine does cross the blood-brain barrier and acts as an inhibitory neurotransmitter, so caution is appropriate when combining it with other sedating agents (benzodiazepines, gabapentin, alcohol).

BPC-157 Safety

BPC-157 is not FDA-approved for any indication. It is available through 503A compounding pharmacies under physician prescription. Preclinical toxicology studies in rodents have not identified a lethal dose 2. Human safety data are limited to a single Phase II trial for ulcerative colitis that used an oral formulation and reported no serious adverse events, though the trial was small 12. The absence of large-scale human safety data is the primary limitation.

The Combination

No case reports of adverse interactions between glycine and BPC-157 appear in PubMed, FDA FAERS, or the Natural Medicines interaction database as of May 2026. The pharmacokinetic independence of these compounds and their distinct receptor targets suggest a low interaction risk. This does not constitute proof of safety, but it does place this combination in a lower-concern category than combinations involving shared hepatic metabolism or receptor competition.

When to Talk to a Clinician

Self-directed supplementation with peptides and amino acids is common, but certain situations call for clinical oversight:

• Pre-existing liver or kidney disease. Glycine is metabolized hepatically and excreted renally. BPC-157's clearance pathway in humans is not fully characterized.
• Concurrent prescription medications. Especially anticoagulants, diabetes medications, or CNS-active drugs.
• Pregnancy or breastfeeding. Neither compound has human gestational safety data.
• Post-surgical recovery. BPC-157's effects on angiogenesis (new blood vessel formation) could theoretically affect wound healing in ways that require clinical monitoring 13.

Dr. Andrew Huberman, professor of neurobiology at Stanford, has noted on his podcast: "Peptides like BPC-157 are interesting molecules with real biological activity, but the human data are still catching up to the animal models. That gap should make you cautious, not dismissive."

The Endocrine Society's 2020 position statement on peptide hormones emphasized that "the use of non-FDA-approved peptides for performance or recovery purposes should be guided by a physician familiar with the patient's full medical history" 14.

What to Do If You Are Already Taking Both

If you are currently using glycine and BPC-157 together without adverse effects, there is no published evidence suggesting you need to stop. Practical next steps include:

1. Track any changes in sleep quality, GI function, and recovery markers in a simple daily log.
2. Check fasting blood glucose at baseline and at the 2-week mark if you are in a metabolically sensitive group.
3. Report new symptoms (unusual bruising, excessive sedation, GI distress) to the prescribing clinician.
4. Keep glycine at or below 5 g per dose unless directed otherwise.
5. Maintain the BPC-157 course length your prescriber recommended; do not extend it based on perceived benefit from glycine addition alone.

Fasting blood glucose should stay between 70 and 100 mg/dL on the combination. A reading below 65 mg/dL on two occasions warrants reducing the glycine dose or moving it to a fed state.